The University of Virginia is conducting a clinical research study for adults ages 18 and over who have recently been diagnosed with multiple myeloma and have not received prior therapy. The purpose of this study is to see if the study medication is safe and useful for treating patients with multiple myeloma. You will participate in either Cohort G or H of this study:

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with refractory BRAF V600E Metastatic Colorectal Cancer for a research study. The purpose of this study is to test the safety of a combination of drugs called ZEN003694, cetuximab, and encorafenib. This drug combination has been tested in animals but has not been tested in people. This study tests different doses of the drug to see which dose is safer for people.

The University of Virginia Comprehensive Cancer Center seeks participants ages 70 and over with Advanced Non-Small Cell Lung Cancer. In this study, you will either get pembrolizumab alone until disease progression, or chemotherapy from study-provided list of allowable choices combined with pembrolizumab for up to 2 years or until disease progression. There is evidence that both immunotherapy and immunotherapy combined with chemotherapy are effective at stabilizing your type of cancer compared to chemotherapy alone.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy for a research study. The purpose of the study is compare an experimental treatment, MK-5684, to the standard treatments for mCRPC, abiraterone acetate and enzalutamide. MK-5684 is considered experimental because it has not been approved by the United States Food and Drug Administration (FDA).

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Metastatic Castration-resistant Prostate Cancer (mCRPC) that progressed on or after prior treatment with one Next generation Hormonal Agent (NHA). The purpose of the study is compare an experimental treatment, MK-5684, to the standard treatments for mCRPC, abiraterone acetate and enzalutamide. MK-5684 is considered experimental because it has not been approved by the United States Food and Drug Administration (FDA).

The UVA Health System Department of Anesthesiology seeks healthy adults ages 18 to 65 for a research study. The purpose of the study is to understand how the brain responds to music that makes you feel different emotions and how that may impact your ability to feel pain.

You may be eligible for this study if you have normal hearing (either naturally or with a hearing device), do not experience chronic pain and do not have high blood pressure.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Advanced Solid Tumors (Including Ovarian, fallopian tube, or peritoneal cancer, Adenocarcinoma of the endometrium [endometrial cancer, uterine cancer, or carcinoma of the uterine corpus] Germ cell tumor) for a research study. The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose for further study (the recommended dose).

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have a high-risk melanoma skin cancer, which is resectable (can be surgically removed). The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab as peri-operative therapy in participants with high-risk melanoma.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation for a research study. This study is for patients who have not received prior treatment for their metastatic colorectal cancer. The purpose of the study is to provide evidence that the addition of the investigational agent onvansertib to standard anti-cancer treatment of FOLFIRI or FOLFOX and bevacizumab will improve treatment results.

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with advanced metastatic EGFR-Mutant non-small cell lung cancer. In this study, you will be randomly assigned to a study group. Depending on your assigned group, you will either receive osimertinib (AZD9291), an EGFR inhibitor, alone, or you will get a combination of osimertinib (AZD9291) and bevacizumab, a VEGF inhibitor, until your cancer returns or spreads, you experience unacceptable side effects, or until you decide to come off the study.